Business
Stoke Therapeutics Announces Presentations from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting
– Data from the positive interim analysis of the Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome will be presented –
About this update from Stoke Therapeutics, Inc.
[{"type":"text","content":"\n– Data from the positive interim analysis of the Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome will be presented –\n\n BEDFORD, Mass.--(BUSINESS WIRE)--\nStoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that five abstracts related to the Company’s work in Dravet syndrome will be presented at the American Epilepsy Society (AES) 2021 Annual Meeting, taking place December 3 – 7, 2021 in Chicago.\n\n“At Stoke, our goal is to develop the first medicine to target the underlying cause of Dravet syndrome, a severe and progressive genetic epilepsy,” said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics. “In addition to our progress in the clinic with STK-001, we continue to build a strong foundational understanding of the non-seizure aspects of the disease with data from our BUTTERFLY Observational study to help evaluate the potential of disease-modifying medicines. We look forward to sharing updates on our progress at this year’s AES annual meeting.”\n\nDetails for the Company’s presentations at AES are as follows:\n\n\nTitle: Interim Safety, PK, and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001, an Antisense Oligonucleotide (ASO), in Children and Adolescents with Dravet Syndrome (DS)\nSession Date & Time: Sunday, December 5 at 12:00 p.m. CT\nPresenter: Linda Laux, M.D., Associate Professor of Pediatrics (Neurology and Epilepsy) at Northwestern University Feinberg School of Medicine and Attending Physician at Ann & Robert H. Lurie Children's Hospital of Chicago\nPoster Number: 2.405\n\n\n\nTitle: SWALLOWTAIL: An Open-Label Extension (OLE) Study for Patients with Dravet Syndrome (DS) who Previously Participated in Studies of STK-001\nSession Date & Time: Sunday, December 5 at 12:00 p.m. CT\nPresenter: Colin Roberts, M.D., Director of the Doernbecher Childhood Epilepsy Program at Oregon Health & Science University\nPoster Number: 2.220\n\n\n\nTitle: ADMIRAL: A UK Open-Label Study to Investigate the Safety and Pharmacokinetics (PK) of Multiple Ascending Doses of Antisense Oligonucleotide (ASO) STK-001 in Children and Adolescents with Dravet Syndrome\nSession Date & Time: Sunday, December 5 at 12:00 p.m....